Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.58 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9381121 | 0.83 | CYP3A4 (0.43) | CYP3A4ALDH1A1TSHRGABRR1GABRA1 | |
| SCHEMBL12478684 | 0.76 | KMT2A (0.51) | ALDH1A1TSHRKDM4EHSD17B10PKM | |
| SCHEMBL9564854 | 0.75 | ALDH1A1 (0.44) | CYP3A4ALDH1A1TSHRGABRR1GABRA1 | |
| SCHEMBL28688811 | 0.74 | CYP3A4 (0.64) | CYP3A4ALDH1A1TSHRNFKB1KDM4E | |
| Imidazole Acetic Acid SCHEMBL49 | 0.74 | — | — | |
| Imidazole Acetic Acid SCHEMBL8482521 | 0.72 | ALDH1A1 (1.00) | CYP3A4ALDH1A1TSHRGABRR1GABRA1 | |
| SCHEMBL8320778 | 0.71 | RARB (0.42) | ALDH1A1MAPTTBXAS1MEN1KMT2A | |
| Imidazole Acetic Acid SCHEMBL15260951 | 0.71 | ALDH1A1 (0.92) | CYP3A4ALDH1A1TSHRGABRR1GABRA1 | |
| SCHEMBL28239625 | 0.70 | HRH3 (0.58) | ALDH1A1CPA1MEN1KMT2A | |
| SCHEMBL798220 | 0.69 | NAPRT (0.45) | CYP3A4ALDH1A1TSHRGABRR1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | claimed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | claimed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | claimed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | claimed |
| WO-2011015641-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-02-10 | — | — | WO | claimed |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| WO-2014027199-A1 | FAK AND FLT3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2014-02-20 | — | — | WO | disclosed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2011015641-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | CYP3A4 2247/4885ALDH1A1 3260/4885TSHR 4877/4885 |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | CYP3A4 2247/4885ALDH1A1 3260/4885TSHR 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.